Harel Insurance Investments & Financial Services Ltd. Boosts Position in Cencora, Inc. $COR

Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Cencora, Inc. (NYSE:COR) by 44.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,468 shares of the company’s stock after buying an additional 7,557 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $8,264,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in COR. Oakworth Capital Inc. purchased a new position in Cencora during the 4th quarter valued at about $26,000. Archer Investment Corp grew its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares in the last quarter. IAG Wealth Partners LLC purchased a new position in Cencora during the 3rd quarter valued at about $30,000. Cloud Capital Management LLC purchased a new position in Cencora during the 3rd quarter valued at about $31,000. Finally, Caitlin John LLC purchased a new position in Cencora during the 3rd quarter valued at about $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $305.89 on Wednesday. The business has a 50 day moving average of $332.27 and a 200 day moving average of $343.21. The company has a market capitalization of $59.50 billion, a price-to-earnings ratio of 36.77, a PEG ratio of 1.42 and a beta of 0.64. Cencora, Inc. has a 1-year low of $271.00 and a 1-year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.73 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 17.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on COR. JPMorgan Chase & Co. lifted their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Evercore set a $360.00 price target on Cencora in a research report on Wednesday, April 8th. Robert W. Baird set a $415.00 price target on Cencora in a research report on Tuesday, January 13th. Wells Fargo & Company lifted their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $398.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.